Avishek K Singh1, Chuanqi Cai1, Sreenivasulu Kilari1, Chenglei Zhao1, Michael L Simeon1, Edwin Takahashi1, Elazer R Edelman2,3, Hyunjoon Joon Kong4, Thanila Macedo1, Ravinder J Singh5, Matthew W Urban1, Rajiv Kumar6, Sanjay Misra7. 1. Department of Radiology, Vascular and Interventional Translational Laboratory, Mayo Clinic, Rochester, Minnesota. 2. Institute for Medical Engineering and Science, Massachusetts Institute of Technology, Cambridge, Massachusetts. 3. Department of Internal Medicine, Brigham and Women's Hospital, Massachusetts, Boston, Massachusetts. 4. Chemical and Biomolecular Engineering, Carle Illinois College of Medicine, Carl R. Woese Institute for Genomic Biology, University of Illinois at Urbana-Champaign, Urbana, Illinois. 5. Department of Laboratory Medicine and Pathology, Mayo Clinic College of Medicine, Mayo Clinic, Rochester, Minnesota. 6. Division of Nephrology and Hypertension, Internal Medicine, Mayo Clinic, Rochester, Minnesota. 7. Department of Radiology, Vascular and Interventional Translational Laboratory, Mayo Clinic, Rochester, Minnesota misra.sanjay@mayo.edu.
Abstract
BACKGROUND: Few therapies prevent venous neointimal hyperplasia (VNH) and venous stenosis (VS) formation in arteriovenous fistulas (AVF). Expression of the immediate early response gene X-1 (Iex-1), also known as Ier3, is associated with VNH and stenosis in murine AVFs. The study aimed to determine if local release of Ier3 long-acting inhibitor 1α,25(OH)2D3 from poly(lactic-co-glycolic acid) (PLGA) nanoparticles embedded in a thermosensitive Pluronic F127 hydrogel (1,25 NP) could affect VNH/VS formation in a large animal model. METHODS: Immediately after AVF creation in a porcine model of renal failure, 1,25 NP or vehicle control was injected into the adventitia space of AVF outflow veins. Scanning electron microscopy and dynamic light scattering characterized drug and control nanoparticles. Animals were sacrificed 3 and 28 days later for gene expression, immunohistologic, magnetic resonance imaging and angiography, and ultrasound analyses. Whole transcriptome RNA sequencing with differential gene expression analysis was performed on outflow veins of AVF. RESULTS: Encapsulation of 1α,25(OH)2D3 in PLGA nanoparticles formed nanoparticles of uniform size that were similar to nanoparticles without 1α,25(OH)2D3. The 1,25 NP-treated AVFs exhibited lower VNH/VS, Ier3 gene expression, and IER-3, MCP-1, CD68, HIF-1α, and VEGF-A immunostaining, fibrosis, and proliferation. Blood flow and lumen area increased significantly, whereas peak systolic velocity and wall shear stress decreased. Treatment increased Young's modulus and correlated with histologic assessment of fibrosis and with no evidence of vascular calcification. RNA sequencing analysis showed changes in the expression of genes associated with inflammatory, TGFβ1, and apoptotic pathways. CONCLUSIONS: Local release of 1,25 NP improves AVF flow and hemodynamics, and reduces stenosis in association with reduction in inflammation, apoptosis, and fibrosis in a porcine model of arteriovenous fistula.
BACKGROUND: Few therapies prevent venous neointimal hyperplasia (VNH) and venous stenosis (VS) formation in arteriovenous fistulas (AVF). Expression of the immediate early response gene X-1 (Iex-1), also known as Ier3, is associated with VNH and stenosis in murine AVFs. The study aimed to determine if local release of Ier3 long-acting inhibitor 1α,25(OH)2D3 from poly(lactic-co-glycolic acid) (PLGA) nanoparticles embedded in a thermosensitive Pluronic F127 hydrogel (1,25 NP) could affect VNH/VS formation in a large animal model. METHODS: Immediately after AVF creation in a porcine model of renal failure, 1,25 NP or vehicle control was injected into the adventitia space of AVF outflow veins. Scanning electron microscopy and dynamic light scattering characterized drug and control nanoparticles. Animals were sacrificed 3 and 28 days later for gene expression, immunohistologic, magnetic resonance imaging and angiography, and ultrasound analyses. Whole transcriptome RNA sequencing with differential gene expression analysis was performed on outflow veins of AVF. RESULTS: Encapsulation of 1α,25(OH)2D3 in PLGA nanoparticles formed nanoparticles of uniform size that were similar to nanoparticles without 1α,25(OH)2D3. The 1,25 NP-treated AVFs exhibited lower VNH/VS, Ier3 gene expression, and IER-3, MCP-1, CD68, HIF-1α, and VEGF-A immunostaining, fibrosis, and proliferation. Blood flow and lumen area increased significantly, whereas peak systolic velocity and wall shear stress decreased. Treatment increased Young's modulus and correlated with histologic assessment of fibrosis and with no evidence of vascular calcification. RNA sequencing analysis showed changes in the expression of genes associated with inflammatory, TGFβ1, and apoptotic pathways. CONCLUSIONS: Local release of 1,25 NP improves AVF flow and hemodynamics, and reduces stenosis in association with reduction in inflammation, apoptosis, and fibrosis in a porcine model of arteriovenous fistula.
Authors: Sanjay Misra; Jeffery D Gordon; Alex A Fu; James F Glockner; Alejandro R Chade; Jaywant Mandrekar; Lilach Lerman; Debabrata Mukhopadhyay Journal: J Surg Res Date: 2006-06-30 Impact factor: 2.192
Authors: Laisel Martinez; Juan C Duque; Marwan Tabbara; Angela Paez; Guillermo Selman; Diana R Hernandez; Chad A Sundberg; Jason Chieh Sheng Tey; Yan-Ting Shiu; Alfred K Cheung; Michael Allon; Omaida C Velazquez; Loay H Salman; Roberto I Vazquez-Padron Journal: J Am Soc Nephrol Date: 2018-01-02 Impact factor: 10.121
Authors: Joy P Walker; Jade S Hiramoto; Warren J Gasper; Philip Auyang; Michael S Conte; Joseph H Rapp; David H Lovett; Christopher D Owens Journal: J Vasc Surg Date: 2014-02-28 Impact factor: 4.268
Authors: Juan C Duque; Marwan Tabbara; Laisel Martinez; Angela Paez; Guillermo Selman; Loay H Salman; Omaida C Velazquez; Roberto I Vazquez-Padron Journal: Surgery Date: 2017-12-11 Impact factor: 3.982
Authors: Ameet K Piryani; Sreenivasulu Kilari; Edwin Takahashi; Randall R DeMartino; Jay Mandrekar; Allan B Dietz; Sanjay Misra Journal: Kidney360 Date: 2021-09-28
Authors: Maheshika Somarathna; Patrick Tj Hwang; Reid C Millican; Grant C Alexander; Tatyana Isayeva-Waldrop; Jennifer A Sherwood; Brigitta C Brott; Isabelle Falzon; Hannah Northrup; Yan-Ting Shiu; Chris J Stubben; John Totenhagen; Ho-Wook Jun; Timmy Lee Journal: Biomaterials Date: 2021-11-18 Impact factor: 15.304
Authors: Yifan Lu; Yu Sun; Keman Xu; Fatma Saaoud; Ying Shao; Charles Drummer; Sheng Wu; Wenhui Hu; Jun Yu; Satya P Kunapuli; John R Bethea; Roberto I Vazquez-Padron; Jianxin Sun; Xiaohua Jiang; Hong Wang; Xiaofeng Yang Journal: Front Immunol Date: 2022-03-07 Impact factor: 7.561